Curis
Curis is a biotechnology company dedicated to developing innovative therapeutics for cancer treatment. They focus on first-in-class and differentiated drugs, aiming to improve and prolong the lives of cancer patients through their research and clinical development programs. Their mission is to develop therapies that slow or prevent cancer progression, effectively 'closing and curi͒ng' cancer, inspired by the musical fermata symbol.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Emavusertib (CA-4948)
An investigational small-molecule inhibitor developed to target IRAK4-driven hematologic malignancies; evaluated in dose-escalation and expansion clinical studies for leukemia and lymphoma.
Fimepinostat
An investigational agent with combined HDAC and PI3K inhibitory activity being evaluated in MYC-altered diffuse large B-cell lymphoma and selected solid tumors; has received orphan drug and fast track designations for DLBCL.
CA-170
An investigational immune checkpoint modulator targeting PD‑1/PD‑L1 and related pathways being evaluated in clinical studies.
CA-327
An investigational immune checkpoint‑directed agent evaluated in early clinical studies for tumors expressing relevant checkpoint markers.
Erivedge (vismodegib)
A hedgehog pathway inhibitor approved for advanced basal cell carcinoma; commercialization and marketing managed via partner arrangements.
Emavusertib
An IRAK4 inhibitor targeted therapy being developed for IRAK4-driven leukemia (AML/MDS) and lymphoma (NHL, CLL, WM).
Emavusertib (CA-4948)
An investigational small-molecule inhibitor developed to target IRAK4-driven hematologic malignancies; evaluated in dose-escalation and expansion clinical studies for leukemia and lymphoma.
Fimepinostat
An investigational agent with combined HDAC and PI3K inhibitory activity being evaluated in MYC-altered diffuse large B-cell lymphoma and selected solid tumors; has received orphan drug and fast track designations for DLBCL.
CA-170
An investigational immune checkpoint modulator targeting PD‑1/PD‑L1 and related pathways being evaluated in clinical studies.
CA-327
An investigational immune checkpoint‑directed agent evaluated in early clinical studies for tumors expressing relevant checkpoint markers.
Erivedge (vismodegib)
A hedgehog pathway inhibitor approved for advanced basal cell carcinoma; commercialization and marketing managed via partner arrangements.
Emavusertib
An IRAK4 inhibitor targeted therapy being developed for IRAK4-driven leukemia (AML/MDS) and lymphoma (NHL, CLL, WM).
Services
Design and sponsorship of Phase I dose-escalation, expansion, and combination studies in hematologic malignancies and selected solid tumors.
Organization of target-focused scientific meetings and forums to present research findings and facilitate collaboration among academic, clinical, and industry stakeholders.
Design and sponsorship of Phase I dose-escalation, expansion, and combination studies in hematologic malignancies and selected solid tumors.
Organization of target-focused scientific meetings and forums to present research findings and facilitate collaboration among academic, clinical, and industry stakeholders.
Expertise Areas
- Early-phase oncology clinical trial management
- Translational science and biomarker-driven development
- Small-molecule oncology drug discovery
- Immuno-oncology therapeutic development
Key Technologies
- Small-molecule kinase inhibitors
- Dual HDAC/PI3K inhibition
- Immune checkpoint modulation
- Therapeutic antibody development